PEDIATRIC CLINICAL TRIALS MARKET ANALYSIS

Children are a special group of people with clear physiological and developmental distinctions from adults. To create age-specific, empirically-verified medicines and interventions and to ascertain and enhance the greatest medical care currently accessible, clinical studies in children are crucial. Children's clinical trials are crucial because they aid in the discovery of the most effective pediatric preventments. Children are not just miniature adults, they have quite diverse physiological processes going on as they transition from infancy through adolescence and maturity. Instead of just altering adult dosages and therapies for children because their bodies function differently, it is critical to develop pediatric-specific medications and preventments.

Global pediatric clinical trials market is estimated to be valued at US$ 14,869.5 million in 2022 and is expected to exhibit a CAGR of 9.3% during the forecast period (2022-2030).

Figure 1. Global Pediatric Clinical Trials Market Share (%), by Clinical Trial Phase, 2022

To learn more about this report, request a free sample copy

Increasing demand for new vaccines and other biologic products to prevent various infectious diseases such as measles, mumps, polio, tuberculosis, rubella, influenza, whooping cough, chickenpox, malaria, and streptococcal pharyngitis is expected to drive the market growth.

Increasing demand for new vaccines and other biologic products to prevent various infectious diseases such as measles, mumps, polio, tuberculosis, rubella, influenza, whooping cough, chickenpox, malaria, and streptococcal pharyngitis is expected to drive the market growth. For instance, according to the Centers for Disease Control and Prevention (CDC) factsheet in 2018, around 470,000 children had active epilepsy in the U.S., which was estimated to be around 0.6% of children aged 0-17 years.

Figure 2. Global Pediatric Clinical Trials Market Share (%), by Region, 2022

To learn more about this report, request a free sample copy

Increasing population of children is expected to drive market growth during the forecast period.

Increasing population of children is expected to drive market growth during the forecast period. For instance, according to Humanium, which is an international child sponsorship  Non-Governmental Organisation (NGO) dedicated to stopping violations of children’s rights throughout the world, stated that the pediatric population in 2021 was about 2.2 billion globally.

Global Pediatric Clinical Trials Market– Impact of Coronavirus (COVID-19) Pandemic

Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. Furthermore, according to the Centers for Disease Control and Prevention, as of April 2, 2020, around 2,572 (1.7%) cases of COVID-19 were registered in patients younger than 18 years in the U.S. Therefore, market players and research institutes are focusing on research and development activities by initiating clinical trials of drugs for the preventment of COVID-19 in children. Similarly, the University of Calgary, which is a public research university located in Alberta, Canada, initiated an observational study on March 18, 2020 to determine the clinical characteristics and outcomes of children potentially infected by COVID-19. Furthermore, research institutes are conducting observational studies to understand the impact of COVID-19 in various hospital departments. For instance, the South Egypt Cancer Institute, which provide medical education, training of researchers and physicians in the oncology field, initiated an observational study on May 15, 2020 to determine the effect of the COVID-19 pandemic on patients in the pediatric cancer care divisions in Egypt and the UAE.

Global Pediatric Clinical Trials Market: Key Developments

In June, 2020, Gilead Sciences initiated phase 2/3 clinical trials, to evaluate the safety, efficacy, tolerability, and pharmacokinetics of Remdesivir, an antiviral drug, in pediatric patients with coronavirus disease 2019 (COVID-19).

In November 2018, Synteract, which is a service clinical research organization (CRO) focused on the emerging biopharma segment, acquired KinderPharm, which is a clinical stage, specialty pharmaceutical company with expert resources focused exclusively on pediatric drug development. This acquisition will help Synteract, to strengthen its pediatric center of development.

Global Pediatric Clinical Trials Market: Restraint

The major factors that hinder growth of the global pediatric clinical trials market include high termination percentage of pediatric clinical trials due to several reasons. Pediatric trials have high percentage of failure due to reasons such as patient accrual. Other issues include behavioral problem and trial conduct issues such as inaccurate dosing, difficulty in formulation, and informative termination along with regulatory issues and drug toxicity during clinical trials.

Key Players

Major players operating in the global pediatric clinical trials market include Syneos Health Inc., IQVIA Holdings, Inc., Charles River Laboratories International Inc., Covance Inc., ICON plc, Pharmaceutical Product Development, LLC, Genentech (F. Hoffmann-La Roche AG), Pfizer, Inc., Bristol - Myers Squibb, GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Johnson & Johnson, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Inc.